Invivyd receives Nasdaq minimum bid price deficiency notice, has until January 19, 2027 to comply
Invivyd received a deficiency letter from Nasdaq on July 23, 2026, after its common stock closed below the $1.00 per share minimum bid price requirement for 30 consecutive business days. The company has until January 19, 2027 to regain compliance by achieving a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days. If it fails to comply by that date, it may be eligible for an additional 180 calendar day period by transferring to The Nasdaq Capital Market, though there is no assurance the company will regain compliance.
- Deficiency letter received July 23, 2026
- Bid price closed below $1.00 per share for 30 consecutive business days
- Initial Compliance Period ends January 19, 2027
- Must achieve closing bid price of at least $1.00 per share for minimum of ten consecutive business days to regain compliance
- May be eligible for additional 180 calendar day period if it transfers to The Nasdaq Capital Market
- Common Stock continues to trade on The Nasdaq Global Market under symbol 'IVVD'
Invivyd faces a defined cure period before potential delisting; if the stock price does not recover to $1.00 or above within the specified windows, the company risks being delisted from Nasdaq.
Derived from 8-K filed 2026-07-24. Not investment advice. Figures are extracted from the filing; prose is AI-assisted. View the source filing on SEC.gov →